Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process TA
ID number 4066

Provisional Schedule

Expected publication 11 October 2023

Project Team

Project lead Thomas Feist

Email enquiries


Companies sponsors AstraZeneca
Patient carer groups Ovacome
  Target Ovarian Cancer
Professional groups Association of Cancer Physicians
  British Gynaecological Cancer Society
  Cancer Research UK
  Royal College of Physicians
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
01 August 2023 Committee meeting: 2
27 June 2023 - 12 July 2023 Draft guidance
06 June 2023 Committee meeting: 1
27 September 2022 Invitation to participate
24 August 2022 Draft scope documents
06 April 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
06 April 2022 In progress. Review of TA693

For further information on our processes and methods, please see our CHTE processes and methods manual